Long-Term Effectiveness and Safety of Ustekinumab in Crohn's Disease: Results from a Large Real-Life Cohort Study.

Ustekinumab (UST) is an interleukin-12/interleukin-23 receptor antagonist approved for the treatment of Crohn's disease (CD). Only limited real-life data on the long-term outcomes of CD patients treated with UST are available. This study assessed UST's long-term effectiveness and safety in a large population-based cohort of moderate to severe CD patients.

The Impact of Inflammatory Bowel Diseases on Patients' Quality of Life and Work Functionality: An Observational Study.

Background: This study aimed to assess the employment status, quality of life, and work functionality in patients affected by inflammatory bowel diseases (IBDs).

Methods: Patients (N = 216) were enrolled between June 2020 and October 2021. Personal, clinical, and occupational features were investigated.

Exploring the concept of deep remission in Crohn's disease: correlation between transmural healing and biomarkers.

Background: While mucosal healing (MH) and transmural healing (TH) predict relevant clinical outcomes in Crohn's disease (CD), little is known about the real significance and clinical impact of deep remission (DR).

Objectives: To better explore the concept of DR, toward a direct correlation between MH, TH, and biomarkers.

Design: Real-world observational longitudinal study to evaluate the rate of clinical remission (CR), MH and TH, and the fecal calprotectin (FC)/C-reactive protein (CRP) levels in all consecutive CD patients on biologics.